Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program
Key claim: The Centers for Medicare & Medicaid Services has issued a final rule establishing permanent regulatory standards for negotiating lower Medicare prescription drug prices and addressing fixed-combination drug formulations.
Abstract
(Rule · Health and Human Services Department, Centers for Medicare & Medicaid Services) This rule finalizes and codifies the Medicare Drug Price Negotiation Program (“Negotiation Program”) and establishes certain new policies for the Negotiation Program and the Medicare Prescription Drug Benefit Program (“Part D Program”) as required by the Inflation Reduction Act of 2022. This final rule also finalizes a proposed policy for specific fixed combination drugs that are new formulations.
Why this matters
The final rule moves Medicare drug-price negotiation standards from proposal to permanent regulation under authority established by the Inflation Reduction Act, providing an operational framework for manufacturers and Part D plans. Treatment of fixed-combination formulations matters for which products fall within negotiated pricing policies, but the finding does not specify affected drugs, effective dates, or changes to individual beneficiaries’ out-of-pocket payments.